GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » DeferredTaxAndRevenue

Aroa Biosurgery (ASX:ARX) DeferredTaxAndRevenue : A$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Aroa Biosurgery's current deferred tax and revenue for the quarter that ended in Mar. 2024 was A$0.00 Mil.

Aroa Biosurgery DeferredTaxAndRevenue Historical Data

The historical data trend for Aroa Biosurgery's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery DeferredTaxAndRevenue Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
DeferredTaxAndRevenue
- - 0.05 - -

Aroa Biosurgery Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
DeferredTaxAndRevenue Get a 7-Day Free Trial 0.05 - - - -

Aroa Biosurgery DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aroa Biosurgery (ASX:ARX) Business Description

Traded in Other Exchanges
N/A
Address
64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines